March 11, 2013

Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum

SOUTH EASTON, Mass., March 11, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at SeeThruEquity's Spring Investor Microcap Forum on Tuesday, March 12th at 3:20 pm EDT. The Investor Forum is being held at the Penn Club, 30 West 44th Street, New York, NY. Registration for the Investor Forum is available at www.seethruequity.com.

Mr. Schumacher's presentation will be webcast and may be viewed on the day of the presentation and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com).

About SeeThruEquity LLC:

SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on small- and micro-cap companies with less than $1 billion in market capitalization. These companies are typically underserved by the traditional Wall Street analyst establishment. SeeThruEquity is unfettered by any ties to investment banking or trading, and distributes its high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to its own audience of investors from its corporate website.

SeeThruEquity's philosophy is focused on delivering an unbiased, institutional quality research product for uncovered or under covered companies to all levels of investors in the investment community and at absolutely no charge to the reader of the research or the company being covered. The firm seeks to build relationships between corporate issuers and institutional and sophisticated investors via compelling investor conferences and forums as well as non-deal road shows.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and

counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President and CEO, PBI	(508) 230-1828 (T)
Conrad F. Mir, CFO, PBI	(508) 230-1828 (T)
Timothy J. Connor, Managing Director, Benchmark Advisory	(858) 568-7059 (T)

SOURCE Pressure BioSciences, Inc.